Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

LunaRx vs PauseRX

LunaRx
Graded #301

Lower grade

vs+7.299999999999997
PauseRX
Graded #149

Higher grade

The verdict

PauseRX takes it — 68.5/100 to 61.2/100.

PauseRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. PauseRX is a nationwide compounded GLP-1 telehealth platform notable for its transparency: it names its 503A pharmacy partner (Strive Pharmacy in Gilbert, AZ), its physician network (Beluga Health), and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePauseRX +12
54
66
Dose & formulationPauseRX +33
52
85
Clinical oversightPauseRX +1
82
83
Labs & monitoringLunaRx +2
54
52
FulfillmentLunaRx +9
70
61
Contract termsLunaRx +14
55
41
LunaRx · left barPauseRX · right bar

The numbers

MetricLunaRxPauseRX
WeighScore61.2/10068.5/100
GradeCC
Scorecard rank#301#149
Semaglutide$199/mo (starting dose, compounded)$199/mo
TirzepatideNot disclosed$249/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
LunaRx

Graded #301 · C

Strengths

  • Pairs GLP-1 with muscle-protective peptides (e.g., CJC-1295/Ipamorelin, NAD+) to defend lean mass during fat loss
  • Structured, physician-directed off-ramp taper with GI-reset support instead of an indefinite prescription
  • Bilingual care in English and Spanish across intake, messaging, and consults
  • Care directed through a named independent medical group (CareNexus Clinic PC); $0 charged if you are not approved
  • Published clinical support hours (Mon–Fri, CT) with phone, email, and secure messaging; cancel anytime

Where it loses points

  • Only a "from $199/mo" starting price is published; tirzepatide and per-tier pricing are confirmed only after a provider review
  • Compounding pharmacy partners are not named on the site — a transparency gap
  • No LegitScript or PCAB verification is displayed
  • States served are not published; the site claims "telehealth nationwide" but the Terms limit service to states where LunaRx is licensed
  • Compounded medications are not FDA-approved (the site discloses this)
PauseRX

Graded #149 · C

Strengths

  • Names its 503A pharmacy partner (Strive Pharmacy, Gilbert AZ) — buyers can independently verify its licensure
  • Names its physician network (Beluga Health) — you can research the clinical platform handling your prescriptions
  • Publishes the FDA compounded-medication disclaimer
  • Corporate legal entity disclosed (PauseRX, Inc.) — uncommon for direct-to-consumer GLP-1 platforms
  • Flat $199 'all doses' compounded semaglutide pricing — no per-tier escalation

Where it loses points

  • States served not listed — site claims nationwide, but you must contact support to confirm availability
  • Restrictive cancellation policy — orders can't be changed or canceled once submitted, and medications can't be returned
  • No named medical director (Beluga Health is the network, not a named MD)
  • LegitScript certification number not shown — badge only, so no direct lookup
  • Insurance not accepted — cash-pay only; HSA/FSA eligibility not confirmed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard